US Blacklisting of WuXi AppTec Fuels Interest in India's Syngene International
A research campus in Bengaluru houses scientists tackling some of modern medicine's toughest challenges, from new cancer therapies to antibody-drug conjugates (ADCs) in oncology. This facility belongs to Syngene International, India's largest integrated Contract Research, Development and Manufacturing Organisation (CRDMO), which has spent over three decades building capabilities rare among pharmaceutical service providers outside China.
For much of the past two years, this effort appeared overlooked. FY26 was a difficult year for Syngene: revenue growth slowed to 3%, EBITDA fell 12%, margins compressed, and profit after tax declined nearly 20%. Then the external environment shifted dramatically.
On 8 June 2026, the US Department of Defense designated WuXi AppTec under Section 1260H as a Chinese military company. While not immediately imposing sanctions, the move significantly pressures global pharmaceutical companies to diversify supply chains away from Chinese CRDMOs. For Syngene, which has built capabilities similar to WuXi's, the timing is pivotal.
Syngene, founded in 1993 and promoted by Biocon, acts as a scientific partner to global pharma, biotech, animal health and consumer health firms. Clients outsource research, development and manufacturing to reduce costs and speed timelines. The company has over 8,300 scientists, 3 million square feet of infrastructure, and supports more than 400 active client programmes. Its client list includes Bristol Myers Squibb, Amgen, Zoetis, Baxter, and Merck KGaA.
What sets Syngene apart from Indian peers is its ability to operate across the entire pharmaceutical value chain, from early drug discovery to commercial manufacturing. It generates revenue through three segments: Discovery Services (34% of FY26 revenue), Development Services (27%), and Manufacturing Services (39%). The integrated model creates sticky customer relationships as scientific knowledge accumulates.
Industry analysts say Syngene's breadth positions it to capture business from companies seeking alternatives to Chinese providers. The company's infrastructure and expertise could serve as a bridge for global pharma navigating geopolitical uncertainties. However, past financial challenges highlight the need for sustained execution.
